On Wednesday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Quiksilver, (NYSE:ZQK), Delta Air Lines, (NYSE:DAL), BioDelivery Sciences International, (NASDAQ:BDSI), Dynegy (NYSE:DYN)
On March 27, 2015 Quiksilver, Inc. (NYSE:ZQK) disclosed that Pierre Agnes, President of Quiksilver, Inc., has been promoted to Chief Executive Officer and added to the Board of Directors; he succeeds Andy Mooney who is no longer with the company. In addition, Greg Healy, Quiksilver’s APAC Region President, has been promoted to President of Quiksilver, Inc., and Bob McKnight has been appointed Chairman.
Quiksilver, Inc. (NYSE:ZQK) decreased -3.78%, and closed at $1.78. The company holds the market capitalization of $317.04M. For the last twelve months, the stock was able to keep return on equity at -245.30%, while return on assets at -24.10%, in response to its return on investment at -28.20%. Its 20-day moving average decreased -6.51%, below 50-day moving average of -12.66%, below 200-day moving average of -24.10% from the latest market price of $1.78. The mean recommendation of analysts for this stock is 2.60. (Where 1=Buy, 5=Sale).
Quiksilver, Inc. (ZQK) designs, develops, and distributes branded apparel, footwear, accessories, and related products mostly for men, women, and children. The company offers its products for various activities, including casual and outdoor lifestyle associated with surfing, skateboarding, snowboarding, BMX and motocross, rally car, and other activities.
Delta Air Lines, Inc. (NYSE:DAL) is partnering with Ant Financial Services Group (“Ant Financial”) and UATP to make it easier for Chinese consumers to purchase airline tickets via delta.com. The move, which sees Delta become the first United States carrier to add Ant Financial’s Alipay payment platform to its website, is part of the airline’s ongoing effort to serve Chinese travelers. UATP’s alternative form of payment processing initiative connects airlines with online payment brands such as Alipay.
Delta Air Lines, Inc. (NYSE:DAL) declined -3.78%, and closed at $43.26. The company has the market capitalization of $37.06 billion. The beta value of the stock is 0.82. On the other hand the stock’s volatility for the week is 2.40%, and for the month is 2.28%. The stock’s price to book ratio is $4.04, however price to sale ratio is $0.88. Analyst’s mean recommendation regarding this stock is 1.70. (Where 1=Buy, 5=Sale).
Delta Air Lines, Inc. (DAL) offers scheduled air transportation for passengers and cargo worldwide. The company works in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
On March 30, 2015 BioDelivery Sciences International, Inc. (NASDAQ:BDSI) disclosed that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel versus placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed. The results of this trial provide data that will allow the company to better refine the protocol criteria to capture a more “enriched” patient population and target site selection.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) fell -3.71%, and closed at $10.11. The stock has the beta value of 2.36, and its volatility for the week is 8.23%, while for the month it is 5.02%. The company has the market capitalization of $549.37 million. The company holds the book value per share of 1.06, whereas cash per share is 1.35. Price to book ratio remained 9.54, while price to sale ratio is 13.60. Analysts mean recommendation for the stock is said to be 1.40 (where 1=Buy, 5=sale).
BioDelivery Sciences International, Inc. (BDSI) a specialty pharmaceutical company, holds in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa.
Dynegy Inc. (NYSE:DYN) along with its fully owned subsidiary, has finalized its acquisition of EquiPower Resources Corp. and Brayton Point Holdings, LLC from Energy Capital Partners (ECP). The transactions include 10 generating stations, capable of generating 6.3 gigawatts of electricity into the New England and PJM power markets. The Company now owns nearly 20,000 MW operating in eight states.
Dynegy Inc. (NYSE:DYN)’s shares picked down -3.60%, and closed at $30.30. The stock volatility for the week is 4.04%, while for the month remained 3.18%. The company holds consensus target price of $38.14.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -2.60 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 26.20% and Annual EPS growth for the past 5 years is considered as 67.80%.
The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).
Dynegy Inc. (DYN) along with its subsidiaries, produces and sells electric energy, capacity, and ancillary services in the United States. It operates in three segments, Coal, IPH, and Gas. The company sells its services on a wholesale basis from its power generation facilities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
